BioLine RX Valuation
| BLRX Stock | ILS 16.50 0.50 2.94% |
At this time, the firm appears to be fairly valued. BioLine RX shows a prevailing Real Value of S16.34 per share. The current price of the firm is S16.5. Our model approximates the value of BioLine RX from analyzing the firm fundamentals such as Current Valuation of (13.02 M), return on equity of -0.37, and Shares Owned By Insiders of 0.25 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor taking in undervalued instruments and trading overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Fairly Valued
Today
Please note that BioLine RX's price fluctuation is somewhat reliable at this time. Calculation of the real value of BioLine RX is based on 3 months time horizon. Increasing BioLine RX's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for BioLine RX is useful when determining the fair value of the BioLine stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of BioLine RX. Since BioLine RX is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioLine Stock. However, BioLine RX's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.5 | Real 16.34 | Hype 16.5 | Naive 17.73 |
The real value of BioLine Stock, also known as its intrinsic value, is the underlying worth of BioLine RX Company, which is reflected in its stock price. It is based on BioLine RX's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of BioLine RX's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioLine RX's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BioLine RX helps investors to forecast how BioLine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioLine RX more accurately as focusing exclusively on BioLine RX's fundamentals will not take into account other important factors: BioLine RX Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining BioLine RX's current stock value. Our valuation model uses many indicators to compare BioLine RX value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioLine RX competition to find correlations between indicators driving BioLine RX's intrinsic value. More Info.BioLine RX is number one stock in price to book category among related companies. It is number one stock in beta category among related companies totaling about 1.65 of Beta per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLine RX by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLine RX's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioLine RX's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BioLine RX's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BioLine RX and how it compares across the competition.
About BioLine RX Valuation
The stock valuation mechanism determines the current worth of BioLine RX on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of BioLine RX. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of BioLine RX based exclusively on its fundamental and basic technical indicators. By analyzing BioLine RX's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of BioLine RX's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioLine RX. We calculate exposure to BioLine RX's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to BioLine RX's related companies.BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.
8 Steps to conduct BioLine RX's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BioLine RX's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BioLine RX's valuation analysis, follow these 8 steps:- Gather financial information: Obtain BioLine RX's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BioLine RX's revenue streams: Identify BioLine RX's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BioLine RX's industry and market trends, including the size of the market, growth rate, and competition.
- Establish BioLine RX's growth potential: Evaluate BioLine RX's management, business model, and growth potential.
- Determine BioLine RX's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BioLine RX's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLine RX. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |